23:19 , Jul 15, 2019 |  BC Extra  |  Financial News

July 15 Financial Quick Takes: RA raises $300M for new fund; plus Alphamab and Castle

RA launches $300M VC fund  RA Capital raised $300 million for its first close-ended venture fund, dubbed Nexus, which will invest in private companies backed by the firm's main fund, RA Capital Healthcare Fund L.P....
22:00 , Jul 11, 2019 |  BC Innovations  |  Product Development

How Zymeworks aims to take on Roche’s $10B HER2 franchise

Zymeworks is going head to head with one of the biggest commercial cancer franchises -- Roche’s Herceptin trastuzumab and Perjeta pertuzumab -- as it pursues clinical proof-of-concept for its protein engineering platform. Pivotal readouts in...
23:40 , Jul 2, 2019 |  BC Extra  |  Company News

Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb

Having gained rights to Incyte’s PD-1 inhibitor, Zai rolled out an immuno-oncology combination strategy it thinks can carve out a space in the crowded Chinese checkpoint inhibitor field. Zai Lab Ltd. (NASDAQ:ZLAB) licensed exclusive rights...
15:40 , Jul 1, 2019 |  BC Extra  |  Company News

Long wait cost Pfizer until BEACON data clinched Array deal

By waiting for a crucial clinical readout that arrived in May 2019, Pfizer watched Array's stock price climb for two years, eventually paying a takeout price that was well over four times the biotech's value...
01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
23:59 , Jun 28, 2019 |  BioCentury  |  Product Development

Why tissue-agnostic drug development needs NGS to go mainstream

Next-generation sequencing is emerging as the rate-limiting factor for how fast and broadly tissue-agnostic drug development will take off in drug development. By engaging community oncologists, some companies hope to spread the word and enable...
01:37 , Jun 28, 2019 |  BC Innovations  |  Product Development

How Array stayed alive long enough to grow up

Array’s 21-year journey as an independent platform company, culminating in an $11.4 billion buyout, required shifting focus from research to development and back again. The acquisition sends a message that developing focused expertise and sticking...
22:41 , Jun 20, 2019 |  BC Innovations  |  Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

A new crop of companies is creating tools to systematize development of allosteric protein inhibitors, finally moving industry beyond the one-off compounds that have been found by accident. Allosteric pockets on proteins have long been...
18:56 , Jun 17, 2019 |  BC Extra  |  Company News

Array takeout buoys biotechs, strengthens Pfizer in targeted oncology

Public biotechs got a boost Monday on the strength of Pfizer's $11.4 billion buyout of Array, signaling that continued M&A interest in the sector can help reverse the loss in momentum that has led to...